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ttp://dx.doi.org/10.1016/j.ajpath.2013.07.031Lymphatic vessels surround follicles within the ovary, but their roles in folliculogenesis and pregnancy,
as well as the necessity of lymphangiogenesis in follicle maturation and health, are undeﬁned. We used
systemic delivery of mF4-31C1, a speciﬁc antagonist vascular endothelial growth factor receptor 3
(VEGFR-3) antibody to block lymphangiogenesis in mice. VEGFR-3 neutralization for 2 weeks before
mating blocked ovarian lymphangiogenesis at all stages of follicle maturation, most notably around
corpora lutea, without signiﬁcantly affecting follicular blood angiogenesis. The numbers of oocytes
ovulated, fertilized, and implanted in the uterus were normal in these mice; however, pregnancies were
unsuccessful because of retarded fetal growth and miscarriage. Fewer patent secondary follicles were
isolated from treated ovaries, and isolated blastocysts exhibited reduced cell densities. Embryos from
VEGFR-3eneutralized dams developed normally when transferred to untreated surrogates. Conversely,
normal embryos transferred into mF4-31C1etreated dams led to the same fetal deﬁciencies observed
with in situ gestation. Although no signiﬁcant changes were measured in uterine blood or lymphatic
vascular densities, VEGFR-3 neutralization reduced serum and ovarian estradiol concentrations during
gestation. VEGFR-3emediated lymphangiogenesis thus appears to modulate the folliculogenic micro-
environment and may be necessary for maintenance of hormone levels during pregnancy; both of these
are novel roles for the lymphatic vasculature. (Am J Pathol 2013, 183: 1596e1607; http://dx.doi.org/
10.1016/j.ajpath.2013.07.031)Supported in part by grants from the NIH (R01-HL075217 to M.A.S.),
the Swiss National Science Foundation (107602 to M.A.S.), and the
American Heart Association (12SDG12050287 to J.M.R.).
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Pytowski approved the manuscript.Ovarian neovascularization provides a unique environment
in which to study physiological adult vasculogenesis apart
from the traditional settings of wound healing and cancer
pathologies. Lymphatic circulation plays a central role in
ﬂuid, lipid, and cellular transport,1 and lymphatic vessels are
present within the ovary and surround follicles during de-
velopment and maturation,2e5 but the importance of the
lymphatic vasculature and lymphangiogenesis in the ovary
is unclear. Consequently, the potential roles of lymphatic
vessels in follicle maturation and pregnancy, and the extent
of involvement or even necessity of maternal lymphangio-
genesis in reproduction, are undeﬁned. This contrasts with
ovarian blood angiogenesis, whose critical roles in follicular
nourishment and maturation and in the formation and
maintenance of the corpus luteum are well appreciated; in-
deed, oocyte fertilization, embryonic implantation, uterinestigative Pathology.
.expansion, and successful gestation all require blood an-
giogenesis.6e8 Lymphangiogenesis, which is often concur-
rent with blood angiogenesis,9 may also play an important
role in these processes.
Adult blood angiogenesis requires signaling via vascular
endothelial growth factor receptor 2 (VEGFR-2), most
potently by VEGF ligation.10,11 In murine ovaries, VEGF
expression increases during angiogenic growth phases,12
and blockade of VEGFR-2 signaling in mice effectively
prevents angiogenesis, resulting in a marked decrease in
Ovarian Lymphatics and Pregnancyovarian weight, blood vessel density, and number of corpora
lutea, and in infertility.13e15 Because gonadotropin treat-
ment apparently does not correct these deﬁciencies,16 it is
likely that follicle maturation and successful pregnancy are
highly dependent on VEGFR-2emediated neovasculari-
zation in the ovary.6,17 Vascularization also occurs in the
uterine wall and decidua during pregnancy, and signiﬁcant
disruption of angiogenesis by VEGFR-2 blockade in these
tissues after fertilization has been shown to greatly reduce
pregnancy success.18
VEGFR-3 is expressed primarily on lymphatic endothe-
lial cells in adult tissue,19,20 and its signaling, via ligation by
VEGF-C or VEGF-D, is necessary for lymphangiogenesis
by inducing lymphatic endothelial cell proliferation and
migration.19e23 Blockade of VEGFR-3 signaling using
a function-blocking antibody such as mF4-31C1 (ImClone
Systems; Eli Lilly, Indianapolis, IN) completely blocks the
initiation of new lymphatic vessels in adult mice without
affecting pre-existing lymphatic morphology or function
and without apparently affecting blood angiogenesis.18,21,22
The ovary contains a dense lymphatic network that has been
morphologically assessed in large rodents.24e26 Recent
studies in which murine ovarian lymphatic vessel expansion
was impaired during development found the dams to be
infertile as adults.3
We investigated VEGFR-3emediated lymphangiogen-
esis and the roles of new lymphatic vessels and lym-
phangiogenesis in female reproduction and found that
lymphangiogenesis occurs within the murine ovary during
reproductive cycles and folliculogenesis and that VEGFR-3
neutralization prevents viable, full-term pregnancies. Using
combined in vivo, ex vivo, and in vitro methods, we
examined which aspects of female fertility are inﬂuenced by
inhibited maternal lymphangiogenesis including oocyte and
follicular development and maturation, uterine implantation,
and embryonic development. After we had eliminated direct
effects on fetal and uterine VEGFR-3emediated neo-
vascularization, our results suggested that the new ovarian
lymphatic vessels speciﬁcally modulate follicle develop-
ment and hormone production, demonstrating a critical and
novel role for ovarian lymphangiogenesis in reproduction.
Materials and Methods
Animal Procedures
All protocols were approved by the Veterinary Authorities
of the Canton Vaud according to Swiss law (protocols 1687,
1988, and 1988.1). mF4-31C1, a function-blocking anti-
body against murine VEGFR-3, was kindly provided by
ImClone Systems.22 For 2 weeks before mating, 0.25 mL of
2.5 mg/mL mF4-31C1 (approximately 32 g/kg) was injected
intraperitoneally every 2 days. For some control groups 0.25
mL saline solution was similarly injected with no adverse
effects on reproductive potential. Three mice were used in
each initial group to test blockade effects.The American Journal of Pathology - ajp.amjpathol.orgFor studies without fertilization, 3-week-old female F1
hybrid mice (C57Bl/6JxCBA/caj; Charles River Laborato-
ries International, L’Arbresle, France; Wilmington, MA)
were treated for 2 weeks and then sacriﬁced (nZ 5 mice per
group). Follicles and ovaries were collected for subsequent
in vitro culture and histological examination.
In studies requiring fertilization, 5- to 6-week-old female
F1 hybrid (C57Bl/6JxCBA/caj) mice were treated for 2
weeks before mating (to ensure spanning two full estrus
cycles). At approximately 7 to 8 weeks of age, mice in es-
trus were mated and coitus was evaluated by the presence of
a vaginal plug 16 hours after mating. For embryo retrieval,
ex vivo culture, and transplantation, mice were sacriﬁced
42 hours after mating and two-cell embryos were collected
by oviduct ﬂushing with M2 medium (Sigma-Aldrich,
St. Louis, MO).
Embryos were implanted into pseudo-pregnant recipient
NMRI mice (Charles River Laboratories International)
according to standard implantation protocols. In brief,
embryos from mF4-31C1etreated and untreated F1 hybrid
donors were implanted into treated and untreated recipients.
Recipient dams (n Z 3 per group) were anesthetized using
100 mg/kg i.p. injection of ketamine and 10 mg/kg i.p.
xylazine). A small midsagittal incision was made over each
oviduct, and the donor embryos were deposited into each
oviduct by mouth pipetting under a stereomicroscope. The
incision was then sutured, and pregnancies were permitted
to continue through day 17. Implantation success was
consistently >90% for all groups.
For examination of fetal development and uterine im-
plantation, mice were sacriﬁced at pregnancy day 17 or after
birth. Implantation spots were counted in the uterus, and
remaining fetuses were scored as normal, grade 1 (normal
size but abnormal coloration), grade 2 (underdeveloped
fetus, in size or limb development), or grade 3 (implanted
cell mass or necrotic fetus). Fetuses were ﬁxed overnight in
4% paraformaldehyde and then were stored in 70% ethanol
until photographed.
In Vitro Follicle Culture and Maturation
To determine the direct effects of in vivo mF4-31C1 treat-
ment on normal follicle maturation potential, ovaries were
isolated from 5-week-old mice after 2 weeks of antibody
treatment. In vitro maturation of preantral follicles was per-
formed as described previously.27,28 In brief, whole ovaries
were placed in 3 mL of L-15 LeibovitzeGlutaMAXmedium
(Life Technologies, Carlsbad, CA) with 10% fetal bovine
serum (HyClone Laboratories, Logan, UT) and 1% penicilline
streptomycin solution (Life Technologies). Preantral follicles
with diameters of 100 to 130 mm were mechanically sepa-
rated from the ovaries, washed, and transferred to individual
10-mL droplets of MEM-a GlutaMAX medium containing
5% fetal bovine serum, 1% ITS (5 mg/mL, insulin, 5 mg/mL,
transferrin, and 5 mg/mL selenium mixture solution; all Life
Technologies), 1% penicillin-streptomycin, and 100 mIU/mL1597
Rutkowski et alrecombinant human follicle-stimulating hormone (Organon;
Merck Sharpe&Dohme, Pfäfﬁkon, Switzerland; EMDMerck,
Billerica, MA). For direct in vitro effects of VEGFR-3 block-
ing, 10 mg/mLmF4-31C1 was added to the culture medium of
wild-type follicles (n Z 14 control; n Z 13 test); diameters
of 10 surviving follicles are reported.
Preantral follicles from control and treated females (nZ 3
mice per group) were induced to mature on day 12 of in vitro
culture by exposure to medium lacking hFSH, but supple-
mented with 2.5 IU/mL hCG-Pregnyl (Organon; Merck) and
5 ng/mL murine epidermal growth factor (Sigma-Aldrich).
After 16 hours, oocytes were retrieved by removing the
follicular cumulus cells using 200 IU/mL of hyaluronidase
(Sigma-Aldrich). Oocytes were classiﬁed by the following
maturation states: germinal vesicle, germinal vesicle break-
down, and metaphase II.
Ex Vivo Development of Two-Cell Embryos
To determine the direct effects of VEGFR-3 inhibition on
preimplantation embryonic development, two-cell embryos
were retrieved from oviducts (nZ 3mice per group) andwere
cultured in four-well dishes containing 400 mL of M16
medium (Sigma-Aldrich). The number of embryos that
developed into the eight-cell, morula, and blastocyst stages
were quantiﬁed and imaged under a Nikon SMZ1000 stereo-
microscope equipped with a Nikon DS-5M monochrome
camera at 66, 90, and 114 hours after mating, respectively.
Differential Staining of Inner Cell Mass and
Trophectoderm Cells
To quantify embryonic development, the numbers of total
blastomere, inner cell mass cells, and trophectoderm cells in
blastocysts were evaluated 72 hours after culture by a
modiﬁcation of the method of Thouas et al.29 In brief,
blastocysts were treated with 1% Triton X-100 (Sigma-
Aldrich) and 0.1 mg/mL propidium iodide (Sigma-Aldrich)
for 5 seconds at room temperature. After two washes with
M2 medium, they were incubated in 0.05 mg/mL bisben-
zimide (Sigma-Aldrich) in 100% ethanol for 2 hours at 4C.
Inner cell mass cells were stained blue by bisbenzimide, and
trophectoderm cells were stained pink by both blue-staining
bisbenzimide and red-staining propidium iodide. The
numbers of cells in each body were counted under a Zeiss
Axiovert 200M microscope by two experienced researchers
(J.E.I. and S.T.L.).
Immunoﬂuorescence, Immunohistochemistry, and
Histology
To visualize lymphatic vessels, ovary and uterus cryosections
(6 mm thick; cold acetoneeﬁxed) were labeled with a primary
antibody to the lymphatic-speciﬁc marker LYVE-1 (1:500,
Upstate 07-538; EMD Millipore). For blood vessels, ovaries
were labeled with a FITC-conjugated primary antibody to1598CD31/PECAM-1 (1:200, 550274; BD Pharmingen, San Jose,
CA). Vessels were also colabeled for VEGFR-3 (1:100,
AF743; R&D Systems, Minneapolis, MN). Sections were also
labeled for the macrophage-speciﬁc surface marker F4/80
(1:50,MCA497; AbD Serotec, Kidlington, UK; Raleigh, NC),
collagen IV (1:1000, 10760; MP Biomedicals, Santa Ana,
CA), and Ki-67 (1:100, M7249; Dako, Carpinteria, CA).
These antibodies were detected with Alexa Fluor 488e or
594econjugated donkey, rabbit, or goat IgG secondary anti-
bodies (1:200, Life Technologies), and nuclei were labeled
with DAPI (Vector Laboratories, Burlingame, CA). Fluores-
cent labeling was observed and imaged using a Zeiss Axiovert
200Mmicroscopewith a Zeiss AxioCamMRmcamera. Slides
were then rinsed and counterstained with H&E, dehydrated,
mounted with Fluka Eukitt mounting medium (Sigma-
Aldrich), and imaged again using a Zeiss AxioCamMRc color
camera. The corresponding ﬂuorescence and chromogenic
images were then compared for identiﬁcation, and subsequent
quantiﬁcation, of follicular development.
To label apoptotic cells, a ﬂuorescence TUNEL kit was
used according to the manufacturer’s instructions (Roche
Diagnostics, Rotkreuz, Switzerland; Indianapolis, IN). Oil
Red O (Sigma-Aldrich) was used to stain lipids in ovarian
frozen sections. Sections were counterstained with he-
matoxylin and immediately mounted with Möwiol-based
mounting medium for imaging.
Hormone Analysis
Serum was collected from all mice when sacriﬁced and
analyzed using enzyme-linked immunosorbent assay (ELISA)
kits for levels of estradiol (Calbiotech, Spring Valley,
CA), progesterone (BioSource; Life Technologies), follicle-
stimulating hormone (Endocrine Technologies, Newark, CA),
and luteinizing hormone (Endocrine Technologies), accord-
ing to the manufacturer’s instructions. Absorbance was mea-
sured using a Tecan Saﬁre2 plate reader (Tecan, Männedorf,
Switzerland). Total ovarian estradiol content was obtained by
homogenizing one ovary in 400 mL of PBS, centrifuging, and
then analyzing the supernatant with ELISA. Ovarian estradiol
was normalized by ovary weight.
F(Ab0)2 Preparation and Veriﬁcation
The approximately 30-kDa Fc region of mF4-31C1 was
removed by enzymatic digestion using a Pierce F(ab0)2
preparation kit (Thermo Fisher Scientiﬁc, Rockford, IL)
according to the manufacturer’s instructions, except that 2
hours of additional digestion time was used. The cleaved
antibody was puriﬁed overnight using a Pierce antibody
clean-up kit. Compared with 10 mg/mL for the full antibody,
for the F(ab0)2 fragment 50 mg/mL was necessary to achieve
complete blockade of VEGFR-3 phosphorylation in human
lymphatic endothelial cells treated with 100 ng/mL VEGF-C
(R&D Systems). Approximately 150 g/kg was used in vivo,
as above.ajp.amjpathol.org - The American Journal of Pathology
Ovarian Lymphatics and PregnancyImage Analysis and Quantiﬁcation
To quantify macrophages, Oil Red Oelabeled and TUNEL-
labeled slides and images of entire ovaries were assembled,
the ovary body was outlined, and the percentage of positive
area measured using MetaMorph software version 6.3
(Molecular Devices, Sunnyvale, CA). For lymphatic and
blood vessel quantiﬁcation, we considered each follicular
maturation state. Each follicle was outlined using a CintiQ
freehand graphics tabletedisplay monitor (Wacom, Otono,
Saitama, Japan). Vessel labeling was deﬁned by ﬂuorescence
threshold, and the number of positive pixels for each follicle
was determined. The average vessel area for each maturation
state was calculated. Follicle maturation states were scored as
follows: 1, preantral follicle (secondary follicle); 2, antral
follicle (small follicle with formed atrium); 3, Graaﬁan
follicle (large follicle with signiﬁcant atrium); and 4, corpus
luteum (Supplemental Figure S1, AeC). These divisions
were consistently identiﬁed across multiple examiners.
Statistical Analysis
For determining statistical signiﬁcance between treatments
in follicle vascularization over the stages of maturation,
follicle survival and maturation, and embryo development,
Student’s t-tests were used to compare factors in treated
versus untreated groups. Two-way analysis of variance
followed by Bonferroni post hoc analysis was used for
hormone levels. Data are expressed as means  SEM.
Results
VEGFR-3 Neutralization Prevents Successful Murine
Pregnancy
Female mice were mated at 6 to 8 weeks of age after 2 weeks
of treatment with i) antieVEGFR-3 neutralizing antibody
(mF4-31C1), ii) saline (control), or iii) no injection (normal).
All treatments were stopped 2 to 3 days before mating.
Normal and control mice were equally successful in giving
birth to normal and healthy pups. Mice treated with mF4-
31C1, however, failed to produce a single live birth in the
three animals initially tested (Figure 1A), despite a normal
number of uterine implantation spots. This unexpected
response suggested thatVEGFR-3 signaling, likelymediating
lymphangiogenesis, is a necessary process in murine preg-
nancy. Indeed, Ki-67 lymphatic endothelial cells were iden-
tiﬁed surrounding maturing follicles (Figure 1B), indicative
of a proliferating and expanding lymphatic vasculature.
Ovarian Lymphangiogenesis, but Not Blood
Angiogenesis, Is Inhibited by VEGFR-3 Blockade
Although mature blood vessels do not express VEGFR-3,
angiogenic blood vessels have been observed to express
VEGFR-3 both during normal development and in tumorsThe American Journal of Pathology - ajp.amjpathol.organd healing wounds,30e32 and there is evidence that VEGFR-
3 inhibition may limit tumor angiogenesis.33,34 Because
blood angiogenesis in the ovary is necessary for preg-
nancy,6e8,16,35 we ﬁrst examined blood vessels to assess
whether mF4-31C1 has any effects on ovarian angiogenesis.
VEGFR-3 expression was not seen on most blood vessels;
colocalization on CD31þ/LYVE-1 vessels occurred only
within corpora lutea (Figure 1, C and D).36 Importantly,
however, blood vascularization area was not signiﬁcantly
affected by VEGFR-3 blockade (P Z 0.168, P Z 0.308,
PZ 0.194, and PZ 0.972 for follicle maturation category 1
through 4, respectively) (Figure 1, E and F), consistent with
that seen in dermal wound healing with mF4-31C1.21,22
LYVE-1þ/VEGFR-3þ lymphatic vessels were observed
surrounding nearly every follicle at all maturation states and
did not penetrate into the follicular body or thecal layers
(Figure 1, BeE).5 The extent of lymphatic vascularization
was dependent on the maturation stage of the follicles, with
secondary and preantral follicles exhibiting only a few
sparse lymphatic vessels. Whereas antral follicles and corpora
lutea exhibited a signiﬁcantly greater peripheral lymphatic
network (Figure 1, EeG). In ovaries from mice treated with
mF4-31C1, the extent of lymphatic vascularization was
greatly reduced at all four stages of follicular maturation, as
measured by vessel density (P Z 0.049, P Z 0.002, P Z
0.028, and PZ 0.036, respectively) (Figure 1G). There was
not a complete absence of lymphatic vessels within the ovary,
consistent with our previous studies, in which VEGFR-3
neutralization prevented lymphangiogenesis but had no
morphological effects on pre-existing lymphatic vessels.21,22
The reduced lymphatic vessel density, mostly around the
follicles and corpora lutea (Figure 1H), indicates that lym-
phangiogenesis is an active process during folliculogenesis,
because blockade of VEGFR-3 prevented only the expansion
of new lymphatic vessels.
VEGFR-3 Neutralization Decreases the Number of
Healthy Follicles but Has No Direct Effect on Their
Quality
To explore the possible effects of VEGFR-3 signaling and
lack of lymphatic vasculature on follicular maturation
potential in virgin mice, preantral follicles (100 to 130 mm)
were retrieved after 2 weeks of treatment for in vitro culture.
Although histological examination of ovaries suggested
greater numbers of preantral follicles in VEGFR-3eblocked
mice (Supplemental Figure S1D), the numbers of healthy
patent preantral follicles successfully retrieved was lower
(P < 0.001) from mF4-31C1etreated mice than from saline-
treated mice (Figure 2A). Fragile contact between the oocyte
and granulosa cells in mF4-31C1etreated ovaries was
observed. (Preantral follicles require interactions between
surrounding granulosa and theca cell layers and the
oocyte.27) These contacts were apparently not due to any loss
of basal lamina integrity, however, as evidenced by collagen
IV, laminin, and perlecan labeling (Supplemental Figure S2),1599
Figure 1 Ovarian and follicular lymphangio-
genesis (but not blood angiogenesis) is inhibited
by VEGFR-3 blockade in the ovary, preventing
successful pregnancy. A: Number of embryo
implantations (white bars) in the uterus of normal,
saline-injected, and VEGFR-3eblocked dams and
live births (gray bars) assessed after delivery.
Dams of viable pups were nursing, and uterine
implantations were assumed to equal pups born. B:
Ki-67þ (red) lymphatic endothelial cell (LYVE-1;
green) nuclei in lymphatic vessels surrounding
follicles (arrowheads). C: Blood vessels (CD31;
green) are mostly negative for VEGFR-3 (red), with
the exception of those within the corpora lutea
(arrow). Because lymphatic vessels also express
CD31, the strong VEGFR-3 colocalization likely
marks lymphatic vessels (arrowhead). D: Ovarian
lymphatic vessels (LYVE-1; green) are positive for
VEGFR-3 (red) (arrowheads). LYVE-1þ/VEGFR-3þ
vessels within the corpora lutea are blood vessels
(arrows). E: The extent of lymphatic vasculature
(LYVE-1; green) surrounding follicles within the
ovary was reduced in VEGFR-3eblocked ovaries;
the blood vasculature and blood angiogenesis
(CD31; red) were unaffected by the treatment. F:
Quantiﬁcation of blood and lymphatic vessel
coverage in preantral follicles (maturation cate-
gory 1), small follicles with formed atrium (matu-
ration category 2), large follicles with signiﬁcant
atrium (maturation category 3), and corpora lutea
(maturation category 4) demonstrated no changes
in blood vessel density with VEGFR-3 blockade,
despite some vessels expressing VEGFR-3. G: There
was a signiﬁcant reduction in lymphatic vessels at
each maturation state with VEGFR-3 blockade.
Note the normal increase in vascularization with
folliculogenesis for both lymphatic and blood
vessels; lymphangiogenesis was speciﬁcally
blocked by VEGFR-3 neutralization. H: Lymphatic
vessels (LYVE-1; green) are clearly visualized
around the hormone-producing corpora lutea
(category 4) (arrows) in normal ovaries (right), but
lacking in VEGFR-3eblocked ovaries (left). *P <
0.05, **P < 0.01, and ***P < 0.001. Scale barZ
200 mm.
Rutkowski et albecause no differences were observed in the gran-
ulosaethecal boundary. Although these contacts could affect
the local in vivo environment, after separation and in vitro
culture both groups of preantral follicles exhibited similar
survival rates; surviving follicles were able to mature nor-
mally ex vivo28 to germinal vesicles and through the germinal
vesicle breakdown and metaphase II phases with equal
success (P Z 0.373, P Z 0.386, and P Z 0.843, respec-
tively) (Figure 2B). Preantral follicles isolated from untreated
mice were cultured directly in the presence of 10 mg/mL
mF4-31C1 in vitro; all follicles survived equally (PZ 0.763)1600and grew to similar sizes (PZ 0.539) (Figure 2, C and D).
Thus, blocking VEGFR-3 in vitro had no direct effect on
isolated follicle growth and maturation.
VEGFR-3 Blocking Does Not Alter Macrophage
Recruitment, Lipid Accumulation, or Apoptosis within
the Ovary
Our combined in vivo and in vitro results suggest that the
failed pregnancies derived from alterations in the follicular
environment due to inhibited lymphangiogenesis. Becauseajp.amjpathol.org - The American Journal of Pathology
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Figure 2 Secondary follicles, once retrieved from the ovaries of treated mice, mature normally in vitro. A: Fewer patent follicles were successfully separated
from collected ovaries in treated mice. B: Follicles and their oocytes separated from ovaries of VEGFR-3etreated mice survive normally; germinal vesicle
oocytes from treated and control mice mature to germinal vesicle breakdown and metaphase II stages using the in vitro drop culture technique at equal rates.
C: Survival of secondary follicles directly treated with the VEGFR-3eblocking antibody in vitro was not inhibited. D: Maturation potential, as determined by
follicle size, was also unaffected by direct VEGFR-3 treatment on the follicles. ***P < 0.001. GV, germinal vesicle; GVBD, germinal vesicle breakdown; MII,
metaphase II; 2, secondary.
Ovarian Lymphatics and Pregnancyimmune function may be important in mediating the
balance between hormone accumulation37 and follicle
maturation and ovulation within the ovary38,39 and
immune-cell trafﬁc through lymphatic vessels,25,26 we
labeled macrophages within the ovaries; however, we
found no differences in density or localization (PZ 0.980)
(Figure 3, A and B).
Lymphatic insufﬁciencies have been linked to excessive
tissue lipid accumulation in skin.40e42 Lipids are necessary
for hormone synthesis by granulosa and luteal cells in the
ovary43,44 and may thus be altered with VEGFR-3 block-
ade. We visualized lipid content in the ovaries via Oil
Red O staining and observed no difference in total amount
(P Z 0.635) or localization of lipid (Figure 3, C and D).
Finally, we sought to determine whether blocking VEGFR-
3 increases cell apoptosis throughout the folliculogenic cycle,
which is a normal ovarian process.45 Consistent with ﬁndings
of others,45,46 apoptotic cells were conﬁned primarily to the
interior layer granulosum of regressing antral follicles,
regressing corpora lutea, and postovulatory cells at the ovarian
wall in both groups (Figure 3E). A similar distribution and
number of TUNELþ cells was seen within the ovary (P Z
0.226) of both groups (Figure 3F). Thus, neither the direct
action of VEGFR-3 neutralization nor the reduced lymphatic
vasculature decreased ovarian cell survival.
VEGFR-3 Neutralization Prior to Fertilization Retards
Embryonic Development
Because pregnancies were unsuccessful in VEGFR-3 neu-
tralized mice, we sought to determine at what stage after
fertilization observable differences could be seen in embryonic
and fetal development.Micewere treated for 2weeks, and then
mated; their uteri were examined at pregnancy days 9 and 17.
We counted no differences in the number of implantation spots
in the uteri of treated versus control mice, but fewer fetusesThe American Journal of Pathology - ajp.amjpathol.orgremained, per implantation spot, in mF4-31C1etreated mice
at pregnancy day 17, although this trend was not signiﬁcant
(PZ 0.12) (Figure 4A).More strikingly, the remaining fetuses
were dramatically smaller and underdeveloped (P < 0.001),
and not likely to be viable (Figure 4, AeC). A majority of
fetuses exhibited severe and symmetric intrauterine growth
restriction, with whole-body reduced growth; fetal size was
independent of position within the uterus. Uteri examined at
pregnancy day 9 did not, however, demonstrate these obvious
visual differences (Supplemental Figure S3).
To determine whether the numbers of ovulated oocytes
and early blastocyst development from VEGFR-3eblocked
mice were normal, mice were sacriﬁced 42 hours after
mating and two-cell embryos were collected. The numbers
of harvested two-cell embryos per mouse did not differ
between saline-treated control mice and mF4-31C1etreated
mice (8  1 and 9  2, respectively). All two-cell embryos
were cultured in vitro to blastocysts with 100% success,
regardless of treatment (Figure 4D); however, cell numbers
within the blastocysts were reduced (P Z 0.027). Blasto-
cysts contain an inner cell mass that develops into the fetus
and trophectoderm cells that develop into the placenta. The
total number of cells in the inner cell mass was signiﬁcantly
reduced in blastocysts cultured from mF4-31C1etreated
mice (P Z 0.003), but not in the corresponding trophecto-
derm (P Z 0.154) (Figure 4, E and F).
Maternal Environment Dictates Proper Fetal
Development or Miscarriage of Transplanted Normal
Embryos
To verify that the maternal gestational environment was
responsible for the observed developmental deﬁciencies,
two-cell embryos were isolated from control or mF4-31C1e
treated donor dams and implanted into control ormF4-31C1e
treated pseudo-pregnant recipient dams. Regardless of the1601
Figure 3 Macrophage recruitment, lipid accu-
mulation, and cell apoptosis in the ovary appear to
be unaffected by VEGFR-3 blockade. A: Macro-
phages (F4/80; red) present in the ovary are
limited to follicular peripheries in both control and
treated ovaries (LYVE-1; green). B: Total F4/80þ
area within the ovary remains unchanged. C: The
ovaries contain large amount of lipids (Oil Red O;
red), particularly in the corpora lutea (arrow-
heads). D: Lipid accumulation (the Oil Red Oþ
area) in the ovary is not signiﬁcantly changed
between conditions. E: Apoptotic cells (TUNEL;
green) are limited to interior granulosa cells
(arrows) of regressing follicles and regular
apoptosis of regressing corpora lutea and corpus
hemorrhagicum (arrowheads) in both treatments.
F: No difference was measured in the percent area
of apoptotic cell nuclei within the ovary with
mF4-31C1 treatment. Scale bars: 200 mm (A and E);
300 mm (B); insets, 2 zoom of main image to
visualize localization.
Rutkowski et altreatment of the donor dam, transplantation of embryos
into normal dams resulted in normal implantation and fetal
development, with only normal, viable fetuses found in the
uterus at pregnancy day 17 (Figure 5A). However, fetal
development of normal embryos in mF4-31C1etreated
recipient dams was inhibited, and fewer than 10% devel-
oped normally (P Z 0.002), despite normal implantation
(Figure 5, B and C). These developmental deﬁciencies were
nearly identical to those observed in previously examined
in situ pregnancies (Figure 4, A and B). This ﬁnding,
coupled with the earlier measured blastocyst retardation,
further supports the notion that early ovarian lymphangio-
genesis is independently necessary both for initial devel-
opment after fertilization and for subsequent successful
maintenance of pregnancy.
Reduction in Ovarian Lymphatic Vessels Alone Appears
to Inhibit Fetal Development
It was previously reported that the rat monoclonal antibody
mF4-31C1 does not sufﬁciently cross the placental barrier.18
Even though treatment was stopped before mating, we
detected low levels of rat IgG in the fetus at day pregnancy1602day 8, although by day 13 it was no longer detected
(Supplemental Figure S4A). We removed the Fc domain of
mF4-31C1 by enzymatic digestion, to prevent transplacental
transport (Supplemental Figure S4, B and C).47 Treatment
with the F(ab0) fragment alone resulted in the same failed
pregnancies and fetal development insufﬁciencies as with
the full-form antibody (Supplemental Figure S4, D and E),
demonstrating that fetal VEGFR-3 inhibition was not the
primary cause of impaired development.
There was no signiﬁcant change in the lymphatic vessel
density of the uterus or the decidua in dams at pregnancy
day 10 with or without blockade of VEGFR-3 (PZ 0.283)
(Figure 6, A and B). There was a small but nonsigniﬁcant
reduction in the uterine blood vessel density at pregnancy
day 10 (PZ 0.083) (Figure 6, A and B), which corroborates
a previous study using a high concentration bolus of mF4-
31C1 after mating that also measured a minor reduction,
but that also demonstrated no subsequent effects on preg-
nancy success with VEGFR-3 blockade.18
In focusing the effects of VEGFR-3 neutralization on the
ovary, we assessed hormone levels during pregnancy that
are critical to the gestational environment and whose gonadal
communication may be lymphatic transport dependent.48ajp.amjpathol.org - The American Journal of Pathology
Figure 4 Pregnancies occur after lym-
phangiogenesis is blocked, but embryonic devel-
opment is severely impaired in the womb. A: In
mice treated with mF4-31C1 before fertilization,
few fetal bodies remained within the uterus at
pregnancy day 17. The percentage is based on
number of fetuses per implantation spot. B:
Fetuses extracted at pregnancy day 17 from
treated animals display a marked deﬁciency from
control animals. They were scored as normal or as
normal sized but discolored (1), deﬁcient size and
underdeveloped (2), and identiﬁable cell masses
(3). C: The majority of fetal bodies are severely
underdeveloped masses. D: Two-cell embryos were
extracted from fertilized VEGFR-3etreated mice
and cultured in vitro. Both two-cell embryos and
blastomeres were identical in appearance to those
taken from control animals. E: Effects of VEGFR-3
blockade prior to fertilization are manifest in
blastocyst cell density. No differences were
observed in the number of trophectodermal cells
(propidium iodide and bisbenzimide; red/blue)
that would later become the placenta, but fewer
cells were identiﬁed in the inner cell mass (ICM)
(bisbenzimide; blue) that would later develop into
the fetus. F: Quantiﬁcation indicated a signiﬁcant
reduction in cell numbers in each mass, compared
with control. *P < 0.05, **P < 0.01, and ***P <
0.001. Scale bars: 100 mm (D); 50 mm (E). GridZ
4 mm.
Ovarian Lymphatics and PregnancyNeither pituitary-secreted follicle-stimulating hormone levels
(P Z 0.567) nor luteinizing hormone levels (P Z 0.676),
important for ovulation and the development of the cor-
pora lutea, were reduced in early pregnancy subsequent to
VEGFR-3 neutralization (Figure 6, C and D). Circulating
progesterone concentrations increased normally in mF4-
31C1etreated dams during pregnancy (Figure 6E). Serum
estradiol, however, was signiﬁcantly reduced (P< 0.001, two-
way analysis of variance) at pregnancy days 6 to 9 and thenThe American Journal of Pathology - ajp.amjpathol.orgreturned to baseline levels for the remainder of the pregnancy
(P < 0.001, Bonferroni post hoc analysis) in dams with
reduced ovarian lymphatic vessels (Figure 6F). Because there
was no signiﬁcant change in progesterone with VEGFR-3
blockade, even when pregnancies were failing late in term,
and because progesterone therapy failed to rescue pregnancy
maintenance (data not shown), this effect appeared to be
estradiol-speciﬁc. With decreased lymphatic vessels, ovarian
weight gain was signiﬁcantly inhibited (P Z 0.018) duringFigure 5 VEGFR-3 blockade in the maternal
gestational environment controls pregnancy
success. A: Both normal and treated embryos
implanted into normal, pseudo-pregnant recipient
dams developed into normal, viable fetuses by
pregnancy day 17. In pseudo-pregnant dams pre-
treated with mF4-31C1, no embryos developed into
normal fetuses, despite normal implantations. B:
Quantiﬁcation of normal and remaining fetuses in
implantation experiments. C: The distribution of
fetal quality at pregnancy day 17 after normal
embryo transfer to mF4-31C1etreated recipients
closely replicates that of in situ fetal development
in VEGFR-3eblocked pregnancies; the majority of
fetuses were severely underdeveloped. **P < 0.01.
Grid Z 4 mm.
1603
Figure 6 Pregnancy failures are attributable
only to the ovarian lymphatic vessels. A: Blood
(CD31; red) and lymphatic (LYVE-1; green) capil-
laries in the uterine wall appear normal in both
mF4-31C1etreated and untreated pregnant dams.
B: Quantiﬁed vessel density exhibited a nonsigniﬁ-
cant decrease in blood vessel density (in accord
with past use of mF4-31C1 in pregnancy); lymphatic
density was unchanged. C and D: Serum levels of
the pituitary-derived reproductive hormones
follicle-stimulating hormone (FSH) (C) and lutei-
nizing hormone (LH) (D) were not signiﬁcantly
affected with mF4-31C1 treatment during early
pregnancy. E: Progesterone levels during gestation
were unaffected by VEGFR-3 blockade or by the
failing fetuses. F: Estradiol was signiﬁcantly
reduced in circulation at pregnancy day 6 to 9 after
VEGFR-3 blockade. G: There was no sustained
weight increase in VEGFR-3eblocked ovaries during
pregnancy. H: Estradiol levels in ovarian homoge-
nates (pg estradiol/mg ovarian protein) were
reduced, mirroring the decrease in circulation. *P<
0.05, ***P < 0.001 between treatments or for
regression line signiﬁcantly different from zero.
Scale bar Z 200 mm. Saline, white bars; VEGFR3-
blocked, shaded (BeF). Open circles, saline; black
squares, VEGFR3-blocked (G and H).
Rutkowski et alpregnancy, and the concentration of estradiol in these ovaries
mirrored the reduced circulating levels (PZ 0.013) over time
(Figure 6, G and H). In total, these data demonstrate that the
ovarian lymphatic vasculature and lymphangiogenesis during
follicle maturation and corpus luteum formation are important
regulators of reproductive capacity.
Discussion
We have demonstrated here that VEGFR-3edependent adult
ovarian lymphangiogenesis occurring during follicle matu-
ration is necessary for successful reproduction. Neutraliza-
tion of VEGFR-3 effectively halted lymphangiogenesis of
maturing follicles within the ovary, but did not visibly affect
blood angiogenesis, macrophage recruitment, lipid accumu-
lation, or cell apoptosis. In the absence of lymphangio-
genesis, there were fewer patent secondary follicles, but
folliculogenesis, ovulation, and fertilization were successful.
Early cultured blastocysts from VEGFR-3eneutralized dams,
however, exhibited reduced cell densities. These embryonic
masses naturally implanted in the uterus, but exhibited growth
restriction and all the pregnancies eventually miscarried; there
were no successful births, despite a normal number of uterine1604implantation spots. Transplanting embryos to untreated dams
permitted normal gestational development.
Although the role of, or even existence of, lymphatic
vessels in the uterine wall, endometrium, and decidua is still
unclear,49e52 wemeasured no major differences in LYVE-1þ
cell densities in these tissues during pregnancy after
VEGFR-3 blockade before mating. A previous report sug-
gested that VEGFR-3 signaling occurs in endometrial
lymphatic vessels,51 but high-dose mF4-31C1 (a dose ﬁve
times higher than in the present study) administered at preg-
nancy day 3.75 had little effect on uterine vascularization and
pregnancy success.18 Similarly, VEGF-C/VEGFR-3 sig-
naling may occur in trophoblast cells, affecting placental
growth and leading to intrauterine growth restriction.53
Indeed, this may explain the reduced blastocyst cell densi-
ties ex vivo. Again, however, delivery of mF4-31C1 at
pregnancy day 3.75 did not limit pregnancy success, so this
deﬁciency is corrected in gestation.18 These results, coupled
with the lowered estradiol levels measured during pregnancy,
suggest that it is speciﬁcally the absence of new follicular
lymphatic vessels in the ovary that limits follicle health and
ovarian support of pregnancy maintenance.ajp.amjpathol.org - The American Journal of Pathology
Ovarian Lymphatics and PregnancyThe ovarian microvasculature is critical in regulating
hormonal transport during pregnancy. Normally, as follicles
mature, the theca layers become vascularized by blood
vessels54 and support follicles by synthesizing estrogen,55
and abnormalities in the theca cell layers can result in
infertility.56 After implantation, proper blood vascularization
is necessary for successful pregnancy,6 and blocking blood
vessel formation in the corpus luteum leads to pregnancy
failure.8 The developing blood vasculature of the corpus
luteum permits this pseudo-organ to function properly,
supplying increased progesterone and estrogen to the uterus
to maintain pregnancy.8,35,57 We ﬁnd lymphangiogenesis and
ovarian lymphatic vessels to be of potentially equal impor-
tance. Indeed, VEGFR-3 blockade had the greatest effect on
decreasing follicle-associated lymphatic capillaries on the
normally dense lymphatic network around corpora lutea.58,59
Lymphatic vessels supply a route by which hormones
produced within the ovary enter systemic circulation.60
Additionally, it has also been suggested that retrograde
transfer of prostaglandin E2 (which is involved inmany crucial
processes of pregnancy, including maintenance of the corpora
lutea) from the uterus to the ovary may occur via lymphatic
transport.35,61 Indeed, various studies indicate that the uterus
has a dense lymphatic network,5 that ovarian lymphatic
vessels and lymphangiogenesis are essential for reproduc-
tion,2,3 and that the lymphangiogenic growth factors VEGF-C
and VEGF-D cycle with estrous.58 The poorly connected
granulosa of isolated follicles and lower levels of estradiol
during pregnancy are likely related.62 The blocked growth of
new lymphatic capillaries during folliculogenesis would
disturb the local hormonal balance with VEGFR-3 neutrali-
zation. The lymphatic vasculature of these follicles is then
insufﬁcient to modulate the corpora lutea and their hormone
secretions during pregnancy. Because VEGFR-3 signaling
(and therefore lymphangiogenesis) was blocked only before
mating, ovulation and fertilization and implantation all
occurred normally in a sufﬁciently vascularized uterus.18 We
have thus isolated a developmental period during which
lymphangiogenesis appears to most critically occur.
The range in development across the same fetal cohort
suggests that what is involved is not a systemic maternal
response to factors such as reducednutrition, glucose levels, or
total circulating hormones. Although it is possible that the
systemic reduction of hormones and ovarian estradiol
production are linked to the poor development in late term
resulting in feedback to the ovary from the uterus that reduces
ovarian hormone production,63 this would also manifest as
equivalent developmental retardation across the cohort. The
differences in fetal size were not correlated with position
within the uterus, but a reduction in uterine and placental blood
ﬂow may lead to intrauterine growth restriction, with reduced
volumetric ﬂow providing fewer nutrients to the fetus.64,65
Because in the present study fetuses appeared normal at
pregnancy day 9, exhibited limb and eye formation, and some
had normal skin vascularization, they were potentially size-
restricted because of decreased placental or uterine bloodThe American Journal of Pathology - ajp.amjpathol.orgﬂow. VEGFR-3 neutralization was stopped before mating, so
it is unlikely to have directly regulated blood ﬂow. Estrogens,
however, are necessary to increase blood ﬂow through the
uterine and myometrial arteries.66,67 The measured reduction
in estradiol levels resulting from mF4-31C1 delivery and
inhibited follicular lymphangiogenesis therefore seems to be
the likely local mediator controlling fetal nutrition.
Maintaining ﬂuid balance and interstitial ﬂuid pressure is
another important role for the lymphatic system. In the ovary,
follicles become increasingly vascularized as they grow and
a ﬂuid-ﬁlled antrum is formed. The interstitial ﬂuid pressure
in antra of developing follicles is approximately 15 mmHg,
regardless of size, and drops rapidly to 5 mmHg immediately
preceding ovulation.68 After ovulation, the interstitial ﬂuid
pressure in the highly vascularized corpus luteum has been
reported at a very high 50 mmHg.68 Ovarian lymphatic
vessels must play a role in modulating these ﬂuid pressures.
Furthermore, concurrent lymphangiogenesis is likely neces-
sary to drain extravasated ﬂuid from the newly formed luteal
blood capillaries26 and may help to regulate hormonal sig-
naling on the luteal cells by controlling interstitial ﬂow.
VEGFR-3 neutralization may also dampen lymphatic pump-
ing responses69 or alter capillary permeability,70 either of
which could limit the ability of existing lymphatic vessels to
balance interstitial ﬂuid pressure.
Lack of follicular lymphatic vessels has been reported in
ADAMTS-1 knockout mice,2,3 and Frizzled4 knockout mice
exhibit low levels of ovarian VEGF-C, the primary ligand to
VEGFR-3.71 Both of these strains are infertile, despite
normal mating behavior; infertility in these mice is consid-
ered to be the result of failed hormone transport, intra-
follicular pressure modulation, or maintenance of the corpus
luteum. Mice possessing a mutation in the VEGFR-3 gene or
with low levels of soluble VEGFR-3 exhibit poor lymphatic
function,41 but are able to reproduce, albeit as heterozygotes
and at a lower success rate than wild-type mice.72,73
In conclusion, our results demonstrate that VEGFR-3e
mediated lymphangiogenesis in the ovary is necessary for
pregnancy. Given that antilymphangiogenic therapies aimed at
preventing tumor metastases are proposed as a cancer
therapy33,34,74 and that prolymphangiogenic therapies are
proposed for treating lymphedema,72,75,76 both targeting the
VEGF-C/DeVEGFR-3 axis, it is critical to understand the role
of lymphangiogenesis in the ovary and the role of reproductive
tissue lymphatic vessels in fertility. Moreover, an increased
knowledge of the physiological role of lymphangiogenesis in
the ovaries may provide insight into causes of infertility (and
into potential therapeutic strategies) and would permit a more
careful examination of the pathological vasculogenesis and
lymphangiogenesis inherent with ovarian cancers.
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